Pluri Inc. (Pluristem Therapeutics Inc.) 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on June 4, 2013, by Pluristem Therapeutics Inc., a Nevada corporation headquartered in Haifa, Israel. The report addresses a significant regulatory event concerning the company's clinical development program.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific operational event rather than financial performance.
Material Changes and Events
- Clinical Hold: The U.S. Food and Drug Administration (FDA) placed a clinical hold on the company's Phase II Intermittent Claudication (IC) study (IND 15038).
- Cause: The hold was issued due to a serious allergic reaction in a study participant that required hospitalization.
- Regulatory Action: The FDA is expected to issue a letter within 30 days detailing specific questions and information requests for the registrant.
Outlook, Risks, and Management Commentary
The filing highlights a material risk to the company's clinical trial timeline and potential future commercialization of the therapy for Intermittent Claudication. Management has acknowledged the notification and anticipates further communication from the FDA regarding the resolution of the safety concern. No financial guidance or forward-looking projections were included in this specific filing.
Investor Verification Checklist
- Verify the specific details of the serious allergic reaction and the number of patients affected.
- Monitor the FDA's upcoming letter for the scope of required responses and potential impact on the study design.
- Assess the potential delay to the Phase II study timeline and its effect on the company's cash burn rate.
- Review subsequent filings for the company's response to the FDA and the status of the clinical hold.